Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Robert Puckrin, Sunita Ghosh, Anthea Peters & Douglas Stewart. (2022) Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. Leukemia & Lymphoma 63:3, pages 583-590.
Read now
Read now
Articles from other publishers (17)
Kunal Jobanputra, Lingaraj Nayak, Hasmukh Jain, Tanuja Shet, Sridhar Epari, V.N. Avinash Bonda, Jayashree Thorat, Bhausaheb Bagal, Siddhartha Laskar, Venkatesh Rangarajan, Archi Agrawal, Sumeet Gujral, Nehal Khanna, Jayant Sastri Goda & Manju Sengar. (2022) “Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country”. Clinical Lymphoma Myeloma and Leukemia 22:10, pages e898-e906.
Crossref
Crossref
Diana Al-Sarayfi, Frederik O. Meeuwes, Müjde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G. N. J. Mutsaers, Lara H. Böhmer, Marjolein W. M. van der Poel, Liane te Boome, Tom van Meerten, Martine E. D. Chamuleau, Josée M. Zijlstra, Mirian Brink & Marcel Nijland. (2022) R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma. Blood Cancer Journal 12:9.
Crossref
Crossref
Joel Wight, Nada Hamad, Belinda A. Campbell, Matthew Ku, Kenneth Lee, Hannah Rose, Tasman Armytage, Maya Latimer, Hui‐Peng Lee, Sze‐Ting Lee, Michael Dickinson, Richard Khor & Emma Verner. (2022) Diffuse large B‐cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal 52:9, pages 1609-1623.
Crossref
Crossref
Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. HoskinsRichard J. KlasaKerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors & Laurie H. Sehn. (2021) Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Advances 5:5, pages 1483-1489.
Crossref
Crossref
Vicki A. Morrison. (2021) Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective. Journal of Geriatric Oncology 12:2, pages 320-325.
Crossref
Crossref
Katrin Schmittlutz & Reinhard Marks. (2021) Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Therapeutic Advances in Hematology 12, pages 204062072199648.
Crossref
Crossref
Nancy L. Bartlett. (2020) Approaches to aggressive B-cell lymphomas in less fit patients. Hematology 2020:1, pages 140-147.
Crossref
Crossref
Pamela Allen. (2020) Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches. Current Oncology Reports 22:11.
Crossref
Crossref
Vicki A. Morrison, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent & Aaron Galaznik. (2020) Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015. Journal of Geriatric Oncology 11:1, pages 41-54.
Crossref
Crossref
Wong Doo, White, Martin, Bassett, Prince, Harrison, Jefford, Winship, Millar, Milne, Seymour & Giles. (2019) The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. Cancers 11:7, pages 928.
Crossref
Crossref
M. Christina Cox, Sabrina Pelliccia, Luigi Marcheselli, Roberta Battistini, Annalisa Arcari, Paola Anticoli Borza, Caterina Patti, Ivana Casaroli, Francesca di Landro, Arianna Di Napoli, Francesca Fabbri, Matteo Caridi, Agostino Tafuri, Guido Bocci & Gerardo Musuraca. (2019) The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. Investigational New Drugs 37:3, pages 548-558.
Crossref
Crossref
Roosa Enni Inkeri Prusila, Pekka Peroja, Esa Jantunen, Taina Turpeenniemi‐Hujanen & Outi Kuittinen. (2019) Treatment of diffuse large B‐cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP‐16). Hematological Oncology 37:2, pages 136-142.
Crossref
Crossref
Svetlana Valer'evna Samarina, A.S. Luchinin, N.V. Minaeva, I.V. Paramonov, D.A. D'yakonov, E.V. Vaneeva, V.A. Rosin & S.V. Gritsaev. (2019) Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma. Clinical oncohematology 12:4, pages 25-30.
Crossref
Crossref
Alden A. Moccia & Catherine Thieblemont. (2018) Curing diffuse large B-cell lymphomas in elderly patients. European Journal of Internal Medicine 58, pages 14-21.
Crossref
Crossref
Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, Francesco Zaja, Emanuela Chimienti, Gerardo Musuraca, Alessandra Tucci, Monica Balzarotti, Monica Tani, Francesca Salvi, Emanuela A. Pesce, Angela Ferrari, Anna M. Liberati, Antonio Spadea, Dario Marino, Maria Bruno-Ventre, Stefano Volpetti, Chiara Bottelli, Elena Ravaioli, Francesco Merli & Michele Spina. (2018) Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Hematological Oncology 36:1, pages 68-75.
Crossref
Crossref
Richard J. Lin, Madhusmita Behera, Catherine S. Diefenbach & Christopher R. Flowers. (2017) Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood 130:20, pages 2180-2185.
Crossref
Crossref
Annalisa Chiappella, Alessia Castellino & Umberto Vitolo. (2016) State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1147-1162.
Crossref
Crossref